Psilocybin (COMP360)

Small molecule

Filedsubmitted

Evidence outlook · regulatory review

Major Depressive Disorder: application submitted to FDA

Rolling NDA submission for COMP360 in treatment-resistant depression underway (2026-08-05). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

NCT05711940: This was a randomized, quadruple-blinded, active-comparator-controlled trial with a large sample size (572 participants) and a primary endpoint (MADRS depression score change) that is a validated, hard clinical measure of disease severity, not a lab biomarker. The primary comparison between the high dose and low-dose control arm reached statistical significance in the favorable direction (p<0.001), meeting the design's own pre-specified success criteria.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Also in development:Post-Traumatic Stress Disorder · Phase 2/3

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (3)
Major Depressive Disorder
NCT07226232 · VA Office of Research and Development
2026-08-03 – 2031-06-30 · Major Depression
What this study did
Phase 2/3 (1)
Post-Traumatic Stress Disorder
Phase 2 (7)
Major Depressive Disorder
NCT06132178 · University of Texas at Austin
2025-01-10 – 2030-12-31 · Treatment Resistant Depression, MDD, Major Depressive Disorder, Recurrent Depression, Depression
What this study did
NCT04433858 · Sheppard Pratt Health System
2021-03-01 – 2026-05-01 · Treatment Resistant Depression
What this study did
NCT04739865 · COMPASS Pathways
2020-08-10 – 2021-10-14 · Treatment Resistant Depression
What this study did
NCT03775200 · COMPASS Pathways
2019-03-01 – 2021-09-27 · Treatment Resistant Depression
What this study did
Post-Traumatic Stress Disorder
NCT05312151 · COMPASS Pathways
2022-06-10 – 2024-02-12 · Post Traumatic Stress Disorder
What this study did
Other / comorbidity
NCT05481736 · COMPASS Pathways
2022-10-12 – 2024-11-18 · Anorexia Nervosa
What this study did
Phase 1 (1)
Other / comorbidity
NCT06258031 · Imperial College London
2022-10-28 – 2024-07-24 · Obsessive-Compulsive Disorder
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT05651126 · King's College London
2022-12-12 – 2024-08-23 · Autism Spectrum Disorder
What this study did
Appears in other studies (82)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (5)
Major Depressive Disorder
NCT06247839 · Sharmin Ghaznavi
2024-09-10 – 2028-06-30 · Major Depressive Disorder
What this study did
NCT06303739 · University of North Carolina, Chapel Hill
2024-04-19 – 2027-03-26 · Refractory Depression, Treatment Resistant Depression
What this study did
NCT06308653 · Usona Institute
2024-03-13 – 2027-01-30 · Depressive Disorder, Major
What this study did
Post-Traumatic Stress Disorder
NCT07703722 · Khyber Medical University Peshawar
2026-04-01 – 2027-11-22 · Major Depressive Disorder, Post-Traumatic Stress Disorder (PTSD)
What this study did
NCT05163496 · University of Washington
2022-03-03 – 2024-06-30 · Burnout, Caregiver, Burnout, Professional, COVID-19, Depression, Post Traumatic Stress Disorder, Moral Injury
What this study did
Phase 2 (51)
Major Depressive Disorder
NCT07210112 · Centre Hospitalier St Anne
2026-06-30 – 2030-06-30 · Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD)
What this study did
NCT06072898 · Sunnybrook Health Sciences Centre
2025-05-28 – 2029-05 · Depressive Disorder, Major Depressive Disorder
What this study did
NCT06592833 · Icahn School of Medicine at Mount Sinai
2025-02-25 – 2029-04 · Major Depressive Disorder
What this study did
NCT07211438 · Centre for Addiction and Mental Health
2026-07-03 – 2029-01 · Treatment-Resistant Depression
What this study did
NCT06943573 · Lakshmi N Yatham
2026-06-15 – 2028-12 · Bipolar II Depression
What this study did
Group PACBT for Depressionnot yet recruiting
NCT07566104 · University of California, Los Angeles
2027-01 – 2028-12 · Depression - Major Depressive Disorder, Psilocybin, Cognitive Behavioral Therapy
What this study did
NCT07373535 · Kyle Greenway
2026-12 – 2028-12 · Treatment-Resistant Major Depressive Disorder
What this study did
NCT07183748 · Beersheva Mental Health Center
2025-12-01 – 2028-06-01 · Treatment Resistant Depression
What this study did
NCT07405606 · Centre for Addiction and Mental Health
2026-03-23 – 2028-06 · Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD)
What this study did
NCT06782724 · University Medical Center Groningen
2025-07-01 – 2028-01-01 · COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis), MS (Multiple Sclerosis), Major Depressive Disorder (MDD), Atypical Parkinson Disease
What this study did
NCT06518720 · Centre for Addiction and Mental Health
2025-04-01 – 2027-12 · Treatment Resistant Depression, Chronic Pain
What this study did
NCT05947383 · Sunstone Medical
2023-10-23 – 2027-11-01 · Cancer, Major Depressive Disorder
What this study did
NCT07216404 · Alan Davis
2026-01-01 – 2027-10-31 · Lung Non-Small Cell Carcinoma, Unipolar Depression
What this study did
NCT06512220 · Centre for Addiction and Mental Health
2025-04-21 – 2027-09 · Treatment Resistant Depression
What this study did
NCT07479550 · Stanford University
2026-07 – 2027-08 · Major Depression
What this study did
NCT04620759 · Johns Hopkins University
2021-04-14 – 2027-03-30 · Major Depressive Disorder, Alcohol Use Disorder
What this study did
NCT06378229 · University Hospital, Ghent
2024-05-21 – 2026-12-31 · Treatment Resistant Depression
What this study did
NCT06341426 · University Health Network, Toronto
2024-02-05 – 2026-12-28 · Major Depressive Disorder, Depression, Treatment-Resistant Depression, Mood Disorders
What this study did
NCT06319378 · Section for Affective Disorders; Northern Stockholm Psychiatry
2024-04-19 – 2026-12 · MDD
What this study did
NCT06230757 · University of Colorado, Denver
2024-07-08 – 2026-05-08 · Major Depressive Disorder, Anhedonia, Treatment Resistant Depression
What this study did
NCT05710237 · Centre for Addiction and Mental Health
2023-07-01 – 2026-04-14 · Treatment-resistant Depression
What this study did
NCT05399498 · University of Chicago
2023-11-01 – 2025-12-01 · Borderline Personality Disorder, Major Depressive Disorder
What this study did
NCT05601648 · Washington University School of Medicine
2023-07-01 – 2025-07-01 · Major Depressive Disorder, Anhedonia
What this study did
NCT05220410 · Sheppard Pratt Health System
2022-03-28 – 2025-05-12 · Treatment Resistant Depression, Suicidal Ideation
What this study did
NCT05383313 · National Institute of Mental Health, Czech Republic
2021-05-01 – 2025-04-30 · Treatment Resistant Depression
What this study did
NCT05675800 · Washington University School of Medicine
2024-01-01 – 2025-03-31 · Major Depressive Disorder
What this study did
NCT05259943 · Rotem Petranker
2023-07-15 – 2025-02-01 · Major Depressive Disorder
What this study did
NCT04959253 · King's College London
2021-06-21 – 2024-12-18 · Treatment Resistant Depression
What this study did
NCT04670081 · Central Institute of Mental Health, Mannheim
2021-06-10 – 2024-12-11 · Treatment-resistant Depression
What this study did
NCT04630964 · Section for Affective Disorders; Northern Stockholm Psychiatry
2021-01-01 – 2024-04-18 · Major Depressive Disorder, Depression
What this study did
NCT04593563 · Maryland Oncology Hematology, PA
2020-09-01 – 2023-10 · Major Depressive Disorder
What this study did
NCT05029466 · Brain and Cognition Discovery Foundation
2021-11-19 – 2023-07-22 · Treatment Resistant Depression
What this study did
NCT05381974 · Massachusetts General Hospital
2022-09-15 – 2023-06-01 · Treatment-Resistant Major Depressive Disorder
What this study did
NCT04433845 · Sheppard Pratt Health System
2021-03-01 – 2023-04-15 · Treatment Resistant Depression
What this study did
NCT05594667 · Cybin Therapeutics Inc.
2023-01-01 – 2023-03-14 · Depression, Major Depressive Disorder, Mild Depression, Moderate Depression, Depressive Disorder
What this study did
NCT03866174 · Usona Institute
2020-01-23 – 2022-06-28 · Depressive Disorder, Major
What this study did
NCT03181529 · Johns Hopkins University
2017-08-10 – 2020-12-02 · Major Depressive Disorder
What this study did
NCT03429075 · Imperial College London
2019-01-07 – 2020-10-17 · Depressive Disorder, Major
What this study did
Post-Traumatic Stress Disorder
NCT07745569 · University of New Mexico
2026-12-31 – 2030-06-30 · PTSD, PTSD - Post Traumatic Stress Disorder, Major Depression, Suicidality
What this study did
NCT07104916 · Anthony P King
2026-09-01 – 2029-12 · Post Traumatic Stress Disorder, Depression - Major Depressive Disorder
What this study did
NCT06141876 · Apex Labs Ltd.
2023-12-15 – 2025-06-15 · Post-traumatic Stress Disorder, Depression
What this study did
Other / comorbidity
NCT07582120 · Washington University School of Medicine
2026-11-01 – 2031-12-15 · Depression
What this study did
NCT07227909 · M.D. Anderson Cancer Center
2026-11-04 – 2031-01-31 · Psilocybin, Neuropathy
What this study did
NCT07610369 · Yale University
2026-07-10 – 2030-07 · Depression, Parkinson's Disease (PD)
What this study did
NCT07756736 · Nicky Mehtani, MD, MPH
2026-12 – 2029-06 · Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)
What this study did
NCT06969170 · Claudio N Soares
2025-05-16 – 2028-12-30 · Generalized Anxiety Disorder (GAD)
What this study did
NCT06455293 · Joshua Woolley, MD, PhD
2024-08-19 – 2028-06 · Parkinson Disease, Depression
What this study did
NCT07072728 · Psyence Australia Pty Ltd
2025-10-01 – 2027-12-30 · Adjustment Disorder, Adjustment Disorder With Anxious Mood, Cancer, Cancer Cachexia, Cancer of Endometrium, Cancer of Kidney, Cancer of Prostate, Cancer of the Breast, Cancer of Stomach, Cancer Melanoma Skin, Cancer Pancreas
What this study did
NCT04932434 · Joshua Woolley, MD, PhD
2021-08-15 – 2024-12-31 · Parkinson Disease, Depression, Anxiety
What this study did
Phase 1/2 (5)
Major Depressive Disorder
NCT07499583 · Indiana University
2027-02-01 – 2031-02-01 · Treatment Resistant Depression, Substance Use Disorders
What this study did
NCT07251491 · James J. Peters Veterans Affairs Medical Center
2026-08-06 – 2028-03-01 · Spinal Cord Injury, Depression - Major Depressive Disorder, Veteran
What this study did
Other / comorbidity
NCT07281352 · University of California, Los Angeles
2026-01-05 – 2027-11-30 · Major Depressive Diorder
What this study did
NCT06898606 · Federal University of Latin American Integration
2024-09-05 – 2026-11-20 · Depressive Disorder
What this study did
NCT00302744 · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
2004-04 – 2008-12 · Anxiety
What this study did
Phase 1 (19)
Major Depressive Disorder
NCT07490353 · Medical University of Vienna
2025-11-01 – 2028-05-31 · Depression - Major Depressive Disorder, Anhedonia
What this study did
NCT06442423 · Yale University
2024-10-17 – 2027-12 · Transdiagnostic, Depression - Major Depressive Disorder, Anxiety, PTSD Symptoms, PTSD, Substance Use, Substance Use Disorder (SUD), OCD
What this study did
NCT06731621 · Centre for Addiction and Mental Health
2024-11-01 – 2027-01 · Treatment Resistant Depression, Autism Spectrum Disorder
What this study did
NCT03554174 · Yale University
2018-02-27 – 2026-12 · Major Depressive Disorder
What this study did
NCT05227612 · University of California, Los Angeles
2023-06-27 – 2025-09-12 · Major Depressive Disorder
What this study did
Post-Traumatic Stress Disorder
NCT07737054 · Tel-Aviv Sourasky Medical Center
2025-07-22 – 2026-12-31 · Post-Traumatic Stress Disorder, PTSD
What this study did
Other / comorbidity
NCT07386730 · Jennifer Mitchell
2026-06-01 – 2030-02 · Anhedonia in Healthy Volunteers, Older Adults (50-90 Years)
What this study did
NCT07433452 · Gabriella Gobbi
2026-09-01 – 2029-09-01 · Healthy Participants, Placebo - Control, Psilocybin
What this study did
NCT07406828 · Trent Emerick
2027-12-31 – 2029-08 · Pain Management, Postoperative Pain
What this study did
NCT06430541 · University of Colorado, Denver
2024-11-21 – 2028-12 · Breast Cancer, Ovarian Cancer
What this study did
NCT07719088 · Charles Raison
2026-11-16 – 2028-12 · Aging, Longevity, Biomarkers of Aging
What this study did
NCT07516405 · University of Colorado, Denver
2026-04-01 – 2028-03 · Healthy Volunteer, Older Adults (65-85 Years)
What this study did
NCT06988319 · Oregon Health and Science University
2026-11-01 – 2027-12-31 · Chronic Pelvic Pain
What this study did
NCT07732166 · Pontifícia Universidade Católica do Rio de Janeiro
2026-04-01 – 2027-12-01 · Healthy Adults
What this study did
NCT07118332 · Yale University
2026-07-06 – 2027-12-01 · Smokers With Chronic Pain
What this study did
NCT07053917 · Johns Hopkins University
2026-02-09 – 2027-03 · Stroke, Chronic Stroke, Intracerebral Haemorrhage, Intracerebral Haemorrhage (ICH), Intracerebral Hemorrhage Basal Ganglia, Ischemic Stroke, Ischemic Stroke and Hemorrhagic Stroke, Hemiparesis After Stroke, Hemiplegia Following Ischemic Stroke, Hemiplegia and Hemiparesis, Hemiplegia and/or Hemiparesis Following Stroke, Middle Cerebral Artery Stroke
What this study did
NCT06506019 · University Health Network, Toronto
2024-10-09 – 2027-01-01 · Bipolar Depression
What this study did
NCT05042466 · NWTraumatherapies
2023-09-03 – 2025-10-03 · Trauma, Nervous System
What this study did
NCT02950467 · Joshua Woolley
2018-01-05 – 2019-12-31 · Distress, Depression, Grief
What this study did
Early phase / not applicable (2)
Major Depressive Disorder
NCT06650800 · Centre Hospitalier Universitaire de Nīmes
2024-11-19 – 2025-06-26 · Depressive Disorder, Depressive Disorder, Treatment-Resistant, Hallucinogens, Reinforcement, Psychology
What this study did
NCT05581797 · University of Otago
2023-03-15 – 2024-06-04 · Depressive Disorder, Treatment-Resistant
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Major Depressive Disorder: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Psilocybin (COMP360): this drugPhase 3Small molecule5-HT2A receptorReliable signal
NCT05711940: COMP006 (NCT05711940), primary endpoint MADRS change at week 6: COMP360 25 mg vs 1 mg difference -3.8 points; p<0.001.
NCT05624268: Change in MADRS total score from baseline to Week 6 (COMP005 trial): COMP360 25 mg vs placebo, mean treatment difference -3.6 points (95% CI -5.7 to -1.5; p<0.001)
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
Brexpiprazole (Rexulti)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT01360645: Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample. (Baseline and Week 14): Brexpiprazole 2 mg/Day + ADT -8.27 Units on a scale (Standard Error 0.61) vs Double-blind Placebo + ADT -5.15 Units on a scale (Standard Error 0.6)
NCT01360632: Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample Set (Baseline and Week 14): Brexpiprazole (1mg) + ADT -7.65 Units on a scale (Standard Error 0.5) | Brexpiprazole (3mg) + ADT -7.98 Units on a scale (Standard Error 0.51) vs Placebo + ADT -6.45 Units on a scale (Standard Error 0.51)
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)Partial signal
NCT03738215: Total Score Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) (Baseline and Week 6): Cariprazine 1.5 mg/Day + ADT -14.1 score on a scale (Standard Error 0.7) | Cariprazine 3 mg/Day + ADT -13.1 score on a scale (Standard Error 0.7) vs Placebo + ADT -11.5 score on a scale (Standard Error 0.7)
Dextromethorphan / Bupropion (Auvelity)ApprovedSmall moleculesigma-1/NMDA, Dopamine/norepinephrine transporterPartial signal
NCT04019704: Change in MADRS Total Score From Baseline to Week 6 (6 weeks): AXS-05 15.91 score on a scale (Standard Error 0.921) vs Placebo 12.04 score on a scale (Standard Error 0.862)
NCT02741791: Primary endpoint, MADRS total score change from baseline to Week 6: -11.6 with AXS-05 vs -9.4 with bupropion (active comparator); difference not statistically significant, p=0.117 missed
Duloxetine (Cymbalta)ApprovedSmall moleculeSerotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET)not yet gradedNo reviewed efficacy summary in this indication
Esketamine (Spravato)ApprovedSmall moleculeNMDA receptorPartial signal
NCT02418585: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis (Baseline up to Day 28 of Double-blind Induction Phase): Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) -21.4 Units on a scale (Standard Deviation 12.32) vs Intranasal Placebo Plus Oral AD -17 Units on a scale (Standard Deviation 13.88)
NCT02417064: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated Measures (MMRM) Analysis (Baseline up to Day 28 of Double-blind Induction Phase): Intranasal Esketamine 56 mg Plus Oral Antidepressant -19 Units on a scale (Standard Deviation 13.86) | Intranasal Esketamine 84 mg Plus Oral AD -18.8 Units on a scale (Standard Deviation 14.12) vs Oral AD Plus Intranasal Placebo -14.8 Units on a scale (Standard Deviation 15.07) missed
Lumateperone (Caplyta)ApprovedSmall moleculeSerotonin 5-HT2A / dopamine D1-D2 receptorWeak signal
NCT05061706: Montgomery-Asberg Depression Rating Scale (Day 43): Lumateperone 42 mg -14.7 units on a scale (Standard Error 0.56) | Placebo -10.2 units on a scale (Standard Error 0.54)
NCT04985942: Montgomery-Åsberg Depression Rating Scale (Day 43): Lumateperone 42 mg -14.7 score on a scale (Standard Error 0.54) | Placebo -9.8 score on a scale (Standard Error 0.53)
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Vortioxetine (Trintellix)ApprovedSmall moleculeSerotonin transporter + multiple 5-HT receptorsPartial signal
NCT00596817: Relapse Within First 24 Weeks of the Double-blind Period Based on a MADRS Total Score >=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator (Within first 24 weeks of the double-blind period): Vortioxetine: 5 or 10 mg 13.2 percentage of patients who relapsed vs Placebo 26 percentage of patients who relapsed
NCT02709655: Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B (Baseline (Week 4 of Phase A), Week 8 of Phase B): Double-Blind: Vortioxetine 10 mg -19.2 units on a scale (Standard Error 1.37) | Double-Blind: Vortioxetine 20 mg -19.94 units on a scale (Standard Error 1.37) vs Double-Blind: Placebo -17.48 units on a scale (Standard Error 1.35) | Double-Blind: Fluoxetine 20 mg -20.78 units on a scale (Standard Error 1.6) missed
AmmoxetinePhase 3Small moleculeSerotonin/norepinephrine transporterPartial signal
NCT06827431: Primary endpoint, week-8 MADRS change: significantly better than placebo (P<0.0001) and numerically better than sertraline (2026-07-27).
Ansofaxine HydrochloridePhase 3Small moleculeSerotonin/norepinephrine/dopamine transporterReliable signal
NCT04853407: MADRS total score change from baseline at Week 8: ansofaxine 80 mg -20.0, ansofaxine 160 mg -19.9, placebo -14.6 (p<0.0001).
AzetukalnerPhase 3Small moleculeKv7 potassium channelnot yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
DeupsilocinPhase 3Small molecule5-HT2A receptorPartial signal
NCT05385783: Primary endpoint (3-week MADRS change vs placebo): -14.08 point difference after a single 12mg dose (p=0.0005, Cohen's d=2.151)
KH607Phase 3Small moleculeGABA-A receptorPartial signalNo reviewed efficacy summary in this indication
LB-102 (methylated Amisulpride)
Phase 3(overall)
Small moleculeDopamine D2/D3 receptor + 5-HT7 receptornot yet gradedNo reviewed efficacy summary in this indication
Lysergide Tartrate (LSD) (DT120)Phase 3Small molecule5-HT2A receptorReliable signal
NCT06941844: Emerge (NCT06941844), primary endpoint LS mean change in MADRS total score at Week 6: DT120 ODT 100 µg -13.3 vs placebo -5.2; LS mean difference -8.1 points; p<0.0001.
Milsaperidone (VHX-896)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
OsavampatorPhase 3Small moleculeAMPA receptor (positive allosteric modulator)Partial signal
NCT05203341: MADRS total score change at Day 28 vs placebo (company topline): one dose -4.3 (p = 0.0159); the other dose -3.0 (p = 0.0873, not significant). Day 56: -7.5 (p = 0.0016) and -3.6 (p = 0.1082).
SeltorexantPhase 3Small moleculeOrexin-2 receptor (OX2R)Partial signal
NCT04533529: Double Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1 (Baseline (Day 1), Day 43): DB Treatment Phase: Seltorexant 20 mg -12.9 Units on a scale (Standard Deviation 9.63) vs Double Blind (DB) Treatment Phase: Placebo -10.5 Units on a scale (Standard Deviation 10.26)
NCT04513912: Response (>=50% MADRS improvement) at week 26: 57.4% seltorexant vs 53.4% quetiapine XR; did not reach statistical significance missed
Solriamfetol (Sunosi)Phase 3Small moleculeDopamine/norepinephrine transporterPartial signal
NCT06360419: In the overall patient population the study did not demonstrate a statistically significant change on the Montgomery-Asberg Depression Rating Scale (MADRS) total score compared to placebo, the study's primary endpoint. Patients with MDD with severe excessive daytime sleepiness (n=51) and without severe EDS (n=295) were randomized to solriamfetol 300 mg or placebo. missed
D-Cycloserine / Lurasidone (NRX-101)Phase 2/3Small moleculeNMDA receptor (glycine site) + dopamine/5-HT receptornot yet gradedNo reviewed efficacy summary in this indication
Mitizodone PhosphatePhase 2/3Small moleculeSerotonin transporter/5-HT receptorWeak signalNo reviewed efficacy summary in this indication
ACP-211Phase 2Small moleculeNMDA receptornot yet gradedNo reviewed efficacy summary in this indication
ALTO-100Phase 2Small moleculeFirst-in-class oral small molecule neural plasticity enhancerPartial signal
NCT05117632: MADRS reduction at Week 6: 15.5 points (biomarker-defined group) vs 10.6 points (biomarker-negative group); clinical response (>=50% MADRS reduction): 61% vs 33%
ALTO-203Phase 2Small moleculeHistamine H3 receptor (antagonist / inverse agonist)Partial signalNo reviewed efficacy summary in this indication
ALTO-300Phase 2Small moleculeMelatonergic (MT) receptors (agonist) + serotonin receptorWeak signalNo reviewed efficacy summary in this indication
Arketamine (PRT042)Phase 2Small moleculeNMDA receptornot yet gradedNo reviewed efficacy summary in this indication
AV-101Phase 2Small moleculeNMDA receptorPartial signal
NCT02484456: Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0): AV 101 (4-chlorokynurenine) 20.22 score on a scale (Standard Error 0.68) vs Placebo 20.56 score on a scale (Standard Error 0.51) missed
BI 1569912Phase 2Small moleculeNMDA receptorPartial signal
NCT06558344: Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): 5 mg BI 1569912 -13.6 Units on a scale (95% CI -17.8 to -9.4) | 10 mg BI 1569912 -10.6 Units on a scale (95% CI -14.5 to -6.7) | 20 mg BI 1569912 -10 Units on a scale (95% CI -12.9 to -7.2) vs Placebo-matching BI 1569912 -10.3 Units on a scale (95% CI -13.1 to -7.5) missed
NCT06280235: Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements from baseline and Day 8, Week 4, Week 6 after first drug administration. MMRM estimates of change from baseline to Week 6 in MADRS total score is reported.): 5 mg BI 1569912 -7.8 units on a scale (95% CI -11 to -4.6) | 10 mg BI 1569912 -11.9 units on a scale (95% CI -15 to -8.7) | 20 mg BI 1569912 -12.3 units on a scale (95% CI -14.6 to -10) vs Placebo -12 units on a scale (95% CI -14.2 to -9.7) missed
BlixeprodilPhase 2Small moleculeNMDA receptorWeak signalFeatured results are safety only in this race
BPL-003 (mebufotenin Benzoate)Phase 2Small molecule5-HT2A receptorPartial signal
NCT05870540: MADRS change from baseline at Day 29: 12 mg BPL-003 -11.1 points vs -5.8 points for 0.3 mg comparator arm (p=0.0038); 8 mg BPL-003 -12.1 points vs 0.3 mg comparator (p=0.0025).
BretisilocinPhase 2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
Cyclobenzaprine (Tonmya)Phase 2Small molecule5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism)not yet gradedNo reviewed efficacy summary in this indication
DT-101Phase 2Small moleculeAMPA receptor (positive allosteric modulator)not yet gradedNo reviewed efficacy summary in this indication
ElunetiromPhase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
Emestedastat (Xanamem)Phase 2Small molecule11-beta-HSD1Partial signal
NCT05657691: Primary endpoint (Attention Composite cognitive score, week 6) missed: least squares mean change 0.32 (emestedastat) vs 0.46 (placebo), difference -0.13 (95% CI -0.32 to 0.06), p=0.17 favouring placebo. (MADRS depression score was only a secondary endpoint, borderline at p=0.05.) missed
Esketamine (CLE-100)Phase 2Small moleculeNMDA receptorPartial signal
NCT06340958: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): CLE-100 -11.66 units on a scale (Standard Error 1.5) vs Placebo -8.7 units on a scale (Standard Error 1.55) missed
NCT04103892: Part B - Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): Part B - CLE-100 (Oral Esketamine) -10.72 units on a scale (Standard Error 1.13) vs Part B - Placebo -9.46 units on a scale (Standard Error 1.31) missed
EvifacotrepPhase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
ForvisirvatPhase 2Small moleculeSIRT6Partial signal
NCT04479852: Change From Baseline to Week 4 in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Baseline to Week 4): SP-624 -12.6 Score on a scale (Standard Error 0.83) vs Placebo -10.8 Score on a scale (Standard Error 0.84) missed
GlyphAllo (allopregnanolone Prodrug) (SPT-300)Phase 2Small moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
GW117Phase 2Small moleculeMelatonin MT1/MT2 receptor + 5-HT2C receptorPartial signal
NCT06796868: Change in HAMD-17 total score from baseline at Week 8 (FAS, n=276): placebo -13.46, GW117 20mg -14.62, 40mg -14.34, 60mg -13.75; numerically greater reductions with GW117 but not statistically significant vs placebo. missed
HS-10353Phase 2Small moleculeGABA-A receptorWeak signal
NCT05195203: Phase 1 SAD (healthy, 2-55mg)/MAD (MDD patients, 15-65mg/day) trial: safe and well tolerated, no dose-adjusting AEs; exploratory HAM-D17 signal at 50mg dose: -4.7 vs placebo (95% CI -8.9 to -0.5), not significant at other doses
Hypidone (YL-0919)Phase 2Small moleculeSerotonin transporter/5-HT1A receptor/sigma-1 receptorPartial signalNo reviewed efficacy summary in this indication
IcalcaprantPhase 2Small moleculeKappa-opioid receptor (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
JNJ-89495120Phase 2Small moleculeMuscarinic M1 receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
LiafensinePhase 2Small moleculeSerotonin/norepinephrine/dopamine transporterReliable signal
NCT05113771: Change in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 42, in DGM4-positive Patients (Baseline to Day 42): Liafensine 1mg -15.4 Units on a Scale (Standard Error 1.25) | Liafensine 2mg -15.5 Units on a Scale (Standard Error 1.3) vs Placebo -11 Units on a Scale (Standard Error 1.31)
NCT01369095: In the CN162-007 study, the adjusted mean (SE) change in MADRS total score was -7.3 (0.830) and -6.6 (0.842) for BMS-820836 of 1 and 2 mg, respectively, and -6.9 (0.602) for the continuation group (P = 0.910). missed
LV232Phase 2Small moleculeSerotonin transporter + 5-HT3 receptorWeak signalNo reviewed efficacy summary in this indication
Mebufotenin (5-MeO-DMT) (GH001)Phase 2Small molecule5-HT2A receptorPartial signal
NCT05800860: Placebo-adjusted MADRS reduction from baseline at Day 8: -15.5 points (LS mean difference -15.5, effect size -2.0, P<0.0001)
NelivaptanPhase 2Small moleculeVasopressin V1B receptorPartial signal
NCT00358631: Change from baseline to Day 56 in HAM-D-17 total score (LS mean, SE): nelivaptan 250mg BID -10.7 (0.94) vs placebo -7.68 (0.95); difference from placebo -3.03 (95% CI -5.66 to -0.39; p=0.0244). 100mg BID nelivaptan and escitalopram 10mg QD arms did not separate from placebo.
NH102Phase 2Small moleculeSerotonin/norepinephrine/dopamine transporter + 5-HT2A receptorPartial signalNo reviewed efficacy summary in this indication
PDC-1421Phase 2BotanicalPolygalae radix extract (active components: tenuifolin, polygalasaponins, etc.)Partial signal
NCT02395978: Change of Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 6 Compared to Placebo for Part II. (From Baseline to Week 6): Part II: 2 PDC-1421 Capsule — ITT population: -13.19 score on a scale (Standard Deviation 9.68); PP population: -13.4 score on a scale (Standard Deviation 9.7) | Part II: 1 PDC-1421 Capsule Plus 1 Placebo — ITT population: -9.21 score on a scale (Standard Deviation 8.32); PP population: -10.4 score on a scale (Standard Deviation 5.18) vs Part II: 2 Placebo — ITT population: -9.2 score on a scale (Standard Deviation 7.98); PP population: -8.6 score on a scale (Standard Deviation 7.61)
Pramipexole / Ondansetron (ALTO-207)Phase 2Small moleculeDopamine D3-preferring D3/D2 receptors (agonist) + 5-HT3 receptornot yet gradedNo reviewed efficacy summary in this indication
RopanicantPhase 2Small moleculeAlpha4beta2 nicotinic acetylcholine receptorPartial signal
NCT06836063: MADRS total score change from baseline vs placebo at Week 6: mean difference -3.572 (FAS, p=0.038), -4.067 (PP set, p=0.023) -- primary endpoint met.
NCT03155503: Safe and well tolerated in healthy subjects at single doses up to 60 mg and multiple doses up to 45 mg once daily. Pharmacokinetics were nonlinear with accumulation on multiple dosing: 1.5- to 2.5-fold higher maximum concentration and 1.6- to 4.0-fold higher AUC from 0 to 24 h on day 14 compared with day 1.
SPN-820Phase 2Small moleculemTORC1Partial signal
NCT05066672: Change From Baseline to Week 4 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. (Baseline to Week 4): NV-5138 (800 or 1600 mg) -12.2 units on a scale (Standard Deviation 9.66) | Placebo -11.6 units on a scale (Standard Deviation 10.64) missed
SPN-821Phase 2Small moleculemTORC1 (mammalian target of rapamycin complex 1) (activator)not yet gradedNo reviewed efficacy summary in this indication
VLS-01Phase 2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
ZelquistinelPhase 2Small moleculeNMDA receptorPartial signal
NCT03726658: Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group (Baseline (Day1) to Day 2): AGN-241751 3mg Daily -9.4 score on a scale (Standard Error 1.57) | AGN-241751 10mg Daily -6.7 score on a scale (Standard Error 1.58) | AGN-241751 25mg Daily -9.5 score on a scale (Standard Error 1.57) vs Placebo Daily -9.3 score on a scale (Standard Error 1.61) missed
ELE-101Phase 1/2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
ALA-3000Phase 1Small moleculeNMDA receptorPartial signalFeatured results are safety only in this race
ApimostinelPhase 1Small moleculeNMDAR agonist/modulatorWeak signalFeatured results are safety only in this race
ENX-104Phase 1Small moleculeDopamine D2/D3 receptor (antagonist)Weak signalNo reviewed efficacy summary in this indication
LY03021Phase 1Small moleculeNorepinephrine/dopamine transporter + GABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
SEP-380135Phase 1Small molecule—Weak signalNo reviewed efficacy summary in this indication
SP-101Phase 1Small moleculeNMDA receptornot yet gradedNo reviewed efficacy summary in this indication
Itruvone
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 67 furthest-along competitors are listed; 2 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Psilocybin (COMP360) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
November 2028 (1)
Phase 2/3Post-Traumatic Stress DisorderRecruiting
Est. primary completion 2028-11 · NCT07570654 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Phase 2Major Depressive DisorderRecruiting
Est. primary completion 2029-12-31 · NCT06132178 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 3Major Depressive DisorderRecruiting
Est. primary completion 2030-12-02 · NCT07226232 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

5 August 2026Filing submittedRolling NDA submission for COMP360 in treatment-resistant depression underway
US, FDA · Source ↗
17 February 2026Topline resultCOMP006 Phase 3 meets primary endpoint
Compass Pathways · Source ↗
23 June 2025Topline resultCOMP005 Phase 3 meets primary endpoint
Compass Pathways · Source ↗